



1Q20 M&A Activity

- GSK was active in the first quarter of 2020 with two divestitures and one acquisition. GSK sold three skin treatment brands, Physiogel, Sunmax, and Ciindo to Mega Labs S.A. and also sold 15 healthcare products to STADA Arzneimittel Aktiengesellschaft for an undisclosed amount. GSK also acquired a 50 percent stake in Japan Vaccine Co., Ltd. from Daiichi Sankyo Company, Limited for an undisclosed amount.
- On March 31, 2020, Amgen completed the acquisition of the remaining 49 percent stake in Amgen Astellas Biopharma K.K. from Astellas Pharma for an undisclosed amount.
- On February 25, 2020, AstraZeneca agreed to sublicense its global rights to Movantik, excluding Europe, Canada, and Israel, to Redhill Biopharma for an upfront payment of \$52.5 million and a further non-contingent payment of \$15 million in 2021.
- On February 5, 2020, Merck & Co., Inc. announced the spin-off of Women's Health, Trusted Legacy Brands and Biosimilars Products. Under the terms of the deal, Merck intends to spin-off products from its Women's Health, trusted Legacy Brands, and Biosimilars products into a yet-to-be-named, independent, publicly traded company.


Trend in Industry EBITDA Multiples¹



Trends in Revenue Growth and EBITDA Margins¹




Relative Stock Price Returns²



¹ Calculated using aggregated data for JNJ, PFE, Novartis, MRK, ABBV, AMGN, Novo, GSK, Sanofi, LLY, GILD, BMY, LSE:AZN, AGN, MYL, TEVA, BHC, MNK, PRGO, ENDP, AMRX.

² The Pharmaceutical Industry is a custom, equal-weighted index constructed with the aforementioned companies.

Purchase Price Allocation (PPA) % from Recent Transactions



Category	Useful Life
Customer Related	15.0
Contingent Consid.	0.0
Tech Related	11.0
Brand Related	14.5
Goodwill	0.0
IPR&D	14.0

Notable M&A Deals



On February 24, 2020, Perrigo announced it has reached a definitive agreement to acquire the oral care assets of High Ridge Brands for \$113 million. The acquisition is subject to bankruptcy court approval in connection with High Ridge Brands' Chapter 11 cases.



On February 20, 2020, Eli Lilly and Company announced the completion of its acquisition of Dermira, Inc. for approximately \$1.1 billion. The acquisition expands Lilly's immunology pipeline with the addition of lebrikizumab, a novel, investigational, monoclonal antibody designed for the treatment of moderate-to-severe atopic dermatitis in adolescent and adult patients.



On January 23, 2020, Sanofi completed the acquisition of Synthorx, Inc. from Avalon Ventures, LLC, Correlation Ventures, OrbiMed Advisors LLC, Medixi Ventures (UK) LLP, and others for approximately \$2.5 billion. The acquisition of Synthorx aligns with Sanofi's R&D strategy, enhancing its position as an emerging leader in the area of oncology and immunology.